Sign inJoin waitlistJoin the waitlist

DR

David Riseberg

Adjunct Assistant Professor · Univ of Maryland Sch of Med

Credentials: · · · ·

History

Univ of Maryland Sch of Med
Present

Hematology and Medical Oncology
1992–1995
Internal Medicine
1989–1992
University of Maryland School of Medicine
1985–1989

Research

Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer
Annals of Surgical Oncology · 1998 · 38 citations
Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage…
Blood · 1996 · 26 citations
Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer
Review · Clinical Medicine Insights Oncology · 2015 · Sole author · 15 citations

JZ
Jo Zujewski
4 papers
JO
Joyce O'Shaughnessy
4 papers
KC
Ken Cowan
4 papers
CC
Catherine Chow
2 papers
KH
Kathy Helzlsouer
2 papers
AT
Anthony Tolcher
1 paper
Crystal Mackall
1 paper
JE
Jennifer Eng-Wong
1 paper · 1 as a fellow
KM
Kevin Mulvey
1 paper
Marc Lippman
1 paper
Paul Okunieff
1 paper
RG
Ronald Gress
1 paper

Clinical trials

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034